Outset Medical Awarded VA Contract Aimed at Improving Dialysis Care for Veterans

What To Know

  • OM) (“Outset”) announced today that the Strategic Acquisition Center (SAC) Office of Procurement, Department of Veterans Affairs awarded a national contract that enables the company's Tablo® Hemodialysis System to be sold into the 106 VA hospitals in the U.
  • “Our honored veterans deserve to have the most advanced dialysis care possible, and it is our great privilege to support them through the SAC contract for hemodialysis care,” said Leslie Trigg, Chair and Chief Executive Officer of Outset Medical.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”) announced today that the Strategic Acquisition Center (SAC) Office of Procurement, Department of Veterans Affairs awarded a national contract that enables the company’s Tablo® Hemodialysis System to be sold into the 106 VA hospitals in the U.S.

VA medical facilities across the U.S. provide dialysis care for 35,000 veterans. While Tablo is already deployed in some of those facilities, the new five-year contract will enable VA centers to acquire consoles to send veterans home and expand usage in the acute setting. The award provides for an indefinite quantity of services and goods during the Indefinite Delivery Indefinite Quantity (IDIQ) Award Contract. As part of one of the three centralized contracting entities within the VA, the SAC has been tasked to create superior procurement solutions that deliver on the VA’s promise to veterans.

“Our honored veterans deserve to have the most advanced dialysis care possible, and it is our great privilege to support them through the SAC contract for hemodialysis care,” said Leslie Trigg, Chair and Chief Executive Officer of Outset Medical. “This partnership with the VA will further our mission to bring a technology-enabled, patient-centered approach to dialysis both in the acute and home setting.”

Outset Medical offers the Tablo Hemodialysis System for kidney patients, which is a first-of-its-kind enterprise solution, FDA-cleared for use across the entire continuum of care — from hospital to home. A connected and intelligent device, Tablo has two-way communication with the cloud, which allows treatment data to be sent electronically and enables physicians to remotely monitor patients so that they feel connected to their medical team while being comfortable at home.

Outset Medical, through SDV Medical, was awarded the contract opportunity for SLED, HHD integrated HD/water purification and IHD integrated HD/water purification dialysis:

  • SLED, or Slow Low Efficiency Dialysis, with Tablo allows for the ability to offer adaptive dialysis specific to a patient’s needs. Incumbent dialysis machines provide either a continuous 24-hour treatment or a short (3-4 hour) treatment, but lack the clinical flexibility to offer treatment durations in between. By contrast, Tablo offers clinicians the flexibility to align treatment time to the patient’s clinical needs.
  • HHD, or home hemodialysis, allows the patient to perform dialysis treatments in their own home, safely and efficiently, using Tablo, which requires only a standard electrical outlet and tap water to operate.
  • IHD, or intermittent hemodialysis, allows for traditional dialysis treatment over a 3 to 4-hour period in a chronic or acute setting.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy